Hepatic steatosis among people living with HIV in Southern Brazil : prevalence and risk factors
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFRGS |
Texto Completo: | http://hdl.handle.net/10183/230474 |
Resumo: | Chronic liver disease is an important cause of morbidity and mortality among people living with human immunodefciency virus (HIV) and is frequently related to non-alcoholic fatty liver disease (NAFLD). The objective is to estimate the prevalence and risk factors of hepatic steatosis among consecutive patients with stable HIV infection on antiretroviral therapy (ART). Also, the use of transient elastography (TE) as a mean to identify a subgroup at risk for non-alcoholic steatohepatitis (NASH) and/or liver fbrosis. HIV infected patients were enrolled between August2016 and February2017. Inclusion criteria: ≥18 years with undetectable HIV viral load. Exclusion criteria: pregnancy; alcohol intake ≥20g/day and co-infection B or C viruses. Patients underwent ultrasound (US) to diagnose liver steatosis. Signifcant fbrosis (≥F2) was estimated if at least one of the following were present: APRI>1.0, FIB4>3 and/ or liver stifness ≥7.1kPa. Subjects with TE≥7.1kPa were proposed a liver biopsy and NAFLD Scoring System (NAS)≥3 was considered as diagnosis of NASH. A total of 98 patients were included. Liver steatosis was diagnosed in 31 patients (31.6%) and was independently associated with male gender, BMI, ALT and total bilirubin levels. The prevalence of signifcant fbrosis assessed by TE, APRI and FIB4 was 26.9%, 6.4% and 3.2%, respectively. Seven patients had a TE result ≥7.1kPa. NASH was found in 5 (83.3%). Among HIV infected patients undergoing ART, almost one third have NAFLD. Neither TE, APRI or FIB4 were able to act as surrogates for signifcant liver fbrosis. Nevertheless, TE≥7.1kPa was able to accurately select a subgroup of patients at risk for NASH. |
id |
UFRGS-2_6781ca7d059816e8eb9f157a6eef4a1e |
---|---|
oai_identifier_str |
oai:www.lume.ufrgs.br:10183/230474 |
network_acronym_str |
UFRGS-2 |
network_name_str |
Repositório Institucional da UFRGS |
repository_id_str |
|
spelling |
Pezzini, Marina FerriCheinquer, HugoAraujo, Alexandre deCerski, Carlos Thadeu SchmidtSprinz, EduardoWolff, Fernando HerzPoeta, Julia2021-10-05T04:26:36Z20202045-2322http://hdl.handle.net/10183/230474001131196Chronic liver disease is an important cause of morbidity and mortality among people living with human immunodefciency virus (HIV) and is frequently related to non-alcoholic fatty liver disease (NAFLD). The objective is to estimate the prevalence and risk factors of hepatic steatosis among consecutive patients with stable HIV infection on antiretroviral therapy (ART). Also, the use of transient elastography (TE) as a mean to identify a subgroup at risk for non-alcoholic steatohepatitis (NASH) and/or liver fbrosis. HIV infected patients were enrolled between August2016 and February2017. Inclusion criteria: ≥18 years with undetectable HIV viral load. Exclusion criteria: pregnancy; alcohol intake ≥20g/day and co-infection B or C viruses. Patients underwent ultrasound (US) to diagnose liver steatosis. Signifcant fbrosis (≥F2) was estimated if at least one of the following were present: APRI>1.0, FIB4>3 and/ or liver stifness ≥7.1kPa. Subjects with TE≥7.1kPa were proposed a liver biopsy and NAFLD Scoring System (NAS)≥3 was considered as diagnosis of NASH. A total of 98 patients were included. Liver steatosis was diagnosed in 31 patients (31.6%) and was independently associated with male gender, BMI, ALT and total bilirubin levels. The prevalence of signifcant fbrosis assessed by TE, APRI and FIB4 was 26.9%, 6.4% and 3.2%, respectively. Seven patients had a TE result ≥7.1kPa. NASH was found in 5 (83.3%). Among HIV infected patients undergoing ART, almost one third have NAFLD. Neither TE, APRI or FIB4 were able to act as surrogates for signifcant liver fbrosis. Nevertheless, TE≥7.1kPa was able to accurately select a subgroup of patients at risk for NASH.application/pdfengScientific reports. London. Vol. 10 (2020), 8282, 6 p.HIVFigado gordurosoPrevalênciaFatores de riscoBrasilHepatic steatosis among people living with HIV in Southern Brazil : prevalence and risk factorsEstrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSTEXT001131196.pdf.txt001131196.pdf.txtExtracted Texttext/plain30140http://www.lume.ufrgs.br/bitstream/10183/230474/2/001131196.pdf.txt95856f3df845dd735c238690e39e8585MD52ORIGINAL001131196.pdfTexto completo (inglês)application/pdf1107129http://www.lume.ufrgs.br/bitstream/10183/230474/1/001131196.pdfc61847d3b9b4fe70eefcc49d0dd7f7d7MD5110183/2304742021-11-20 06:05:03.727324oai:www.lume.ufrgs.br:10183/230474Repositório InstitucionalPUBhttps://lume.ufrgs.br/oai/requestlume@ufrgs.bropendoar:2021-11-20T08:05:03Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false |
dc.title.pt_BR.fl_str_mv |
Hepatic steatosis among people living with HIV in Southern Brazil : prevalence and risk factors |
title |
Hepatic steatosis among people living with HIV in Southern Brazil : prevalence and risk factors |
spellingShingle |
Hepatic steatosis among people living with HIV in Southern Brazil : prevalence and risk factors Pezzini, Marina Ferri HIV Figado gorduroso Prevalência Fatores de risco Brasil |
title_short |
Hepatic steatosis among people living with HIV in Southern Brazil : prevalence and risk factors |
title_full |
Hepatic steatosis among people living with HIV in Southern Brazil : prevalence and risk factors |
title_fullStr |
Hepatic steatosis among people living with HIV in Southern Brazil : prevalence and risk factors |
title_full_unstemmed |
Hepatic steatosis among people living with HIV in Southern Brazil : prevalence and risk factors |
title_sort |
Hepatic steatosis among people living with HIV in Southern Brazil : prevalence and risk factors |
author |
Pezzini, Marina Ferri |
author_facet |
Pezzini, Marina Ferri Cheinquer, Hugo Araujo, Alexandre de Cerski, Carlos Thadeu Schmidt Sprinz, Eduardo Wolff, Fernando Herz Poeta, Julia |
author_role |
author |
author2 |
Cheinquer, Hugo Araujo, Alexandre de Cerski, Carlos Thadeu Schmidt Sprinz, Eduardo Wolff, Fernando Herz Poeta, Julia |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Pezzini, Marina Ferri Cheinquer, Hugo Araujo, Alexandre de Cerski, Carlos Thadeu Schmidt Sprinz, Eduardo Wolff, Fernando Herz Poeta, Julia |
dc.subject.por.fl_str_mv |
HIV Figado gorduroso Prevalência Fatores de risco Brasil |
topic |
HIV Figado gorduroso Prevalência Fatores de risco Brasil |
description |
Chronic liver disease is an important cause of morbidity and mortality among people living with human immunodefciency virus (HIV) and is frequently related to non-alcoholic fatty liver disease (NAFLD). The objective is to estimate the prevalence and risk factors of hepatic steatosis among consecutive patients with stable HIV infection on antiretroviral therapy (ART). Also, the use of transient elastography (TE) as a mean to identify a subgroup at risk for non-alcoholic steatohepatitis (NASH) and/or liver fbrosis. HIV infected patients were enrolled between August2016 and February2017. Inclusion criteria: ≥18 years with undetectable HIV viral load. Exclusion criteria: pregnancy; alcohol intake ≥20g/day and co-infection B or C viruses. Patients underwent ultrasound (US) to diagnose liver steatosis. Signifcant fbrosis (≥F2) was estimated if at least one of the following were present: APRI>1.0, FIB4>3 and/ or liver stifness ≥7.1kPa. Subjects with TE≥7.1kPa were proposed a liver biopsy and NAFLD Scoring System (NAS)≥3 was considered as diagnosis of NASH. A total of 98 patients were included. Liver steatosis was diagnosed in 31 patients (31.6%) and was independently associated with male gender, BMI, ALT and total bilirubin levels. The prevalence of signifcant fbrosis assessed by TE, APRI and FIB4 was 26.9%, 6.4% and 3.2%, respectively. Seven patients had a TE result ≥7.1kPa. NASH was found in 5 (83.3%). Among HIV infected patients undergoing ART, almost one third have NAFLD. Neither TE, APRI or FIB4 were able to act as surrogates for signifcant liver fbrosis. Nevertheless, TE≥7.1kPa was able to accurately select a subgroup of patients at risk for NASH. |
publishDate |
2020 |
dc.date.issued.fl_str_mv |
2020 |
dc.date.accessioned.fl_str_mv |
2021-10-05T04:26:36Z |
dc.type.driver.fl_str_mv |
Estrangeiro info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10183/230474 |
dc.identifier.issn.pt_BR.fl_str_mv |
2045-2322 |
dc.identifier.nrb.pt_BR.fl_str_mv |
001131196 |
identifier_str_mv |
2045-2322 001131196 |
url |
http://hdl.handle.net/10183/230474 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.pt_BR.fl_str_mv |
Scientific reports. London. Vol. 10 (2020), 8282, 6 p. |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRGS instname:Universidade Federal do Rio Grande do Sul (UFRGS) instacron:UFRGS |
instname_str |
Universidade Federal do Rio Grande do Sul (UFRGS) |
instacron_str |
UFRGS |
institution |
UFRGS |
reponame_str |
Repositório Institucional da UFRGS |
collection |
Repositório Institucional da UFRGS |
bitstream.url.fl_str_mv |
http://www.lume.ufrgs.br/bitstream/10183/230474/2/001131196.pdf.txt http://www.lume.ufrgs.br/bitstream/10183/230474/1/001131196.pdf |
bitstream.checksum.fl_str_mv |
95856f3df845dd735c238690e39e8585 c61847d3b9b4fe70eefcc49d0dd7f7d7 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS) |
repository.mail.fl_str_mv |
lume@ufrgs.br |
_version_ |
1817725116744728576 |